Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 2.6%. By the end of trading, Actavis fell $3.33 (-1.6%) to $202.94 on average volume. Throughout the day, 2,284,623 shares of Actavis exchanged hands as compared to its average daily volume of 2,482,500 shares. The stock ranged in price between $202.91-$209.71 after having opened the day at $207.16 as compared to the previous trading day's close of $206.27. Other companies within the Drugs industry that declined today were:




), down 39.4%,




), down 19.3%,

Aastrom Biosciences



), down 15.2% and




), down 13.1%.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $35.9 billion and is part of the health care sector. Shares are up 22.8% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk.

On the positive front,

Keryx Biopharmaceuticals



), up 17.4%,

Fate Therapeutics



), up 11.6%,

Conatus Pharmaceuticals



), up 6.2% and

China Biologic Products



), up 6.1% , were all gainers within the drugs industry with




) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.